Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
Effective use of hydroxyurea for sickle cell anemia in low-resource countries.
复制标题
DOI：
10.1097/moh.0000000000000582
复制
发表时间：
2020-05
影响因子：
3.2
通讯作者：
Ware, Russell E.
中科院分区：
文献类型：
--
作者：
Power-Hays, Alexandra;Ware, Russell E.
在过去的几十年里，羟基脲已成为一种安全有效的疾病缓解治疗儿童和成人镰状细胞贫血（SCA）。来自美国国立卫生研究院、美国血液学会和英国血液学会的强有力的循证建议证明，羟基脲现在是SCA的标准治疗方法。然而，在低资源环境中，由于缺乏可用性、治疗指导不足和成本过高，很少使用羟基脲。在加勒比海和撒哈拉以南非洲地区进行的研究试验证实，在资源匮乏的国家，羟基脲是一种安全、可行和有益的治疗方法。因此，羟基脲对于实现世界卫生组织概述的SCA控制目标至关重要。为了最大限度地提高其在现实世界中的有效性，必须特别注意医疗保健提供者的教育和培训，公众和机构的认识，以及药物的可及性和可负担性。在低资源国家有效引进羟基脲的努力应紧急解决缺乏治疗指南、知识和临床基础设施方面的差距以及无法获得药物的问题。政府、学术、制药和慈善组织之间的合作伙伴关系必须解决这些障碍，以便全世界所有SCA患者都能从羟基脲中受益。
Over the past several decades, hydroxyurea has emerged as a safe and potent disease-modifying therapy for children and adults with sickle cell anemia (SCA). Strong, evidence-based recommendations from the National Institutes of Health, American Society of Hematology, and British Society of Haematology document that hydroxyurea is now standard of care treatment for SCA. In low-resource settings, however, hydroxyurea is rarely utilized due to lack of availability, inadequate treatment guidance, and excessive costs. Research trials conducted within the Caribbean and sub-Saharan Africa confirm the efficacy of hydroxyurea as a safe, feasible, and beneficial treatment in low-resource countries. Hydroxyurea is therefore vital to reaching the targets for control of SCA outlined by the World Health Organization. To maximize its utilization toward real-world effectiveness, specific attention must be given to healthcare provider education and training, public and institutional awareness, and medication access and affordability. Efforts to introduce hydroxyurea effectively into low-resource countries should urgently address the lack of treatment guidelines, gaps in knowledge and clinical infrastructure, and medication inaccessibility. Partnerships among governmental, academic, pharmaceutical, and charitable organizations must tackle these barriers so that all individuals living with SCA worldwide can benefit from hydroxyurea.
扩大现有神经疾病（扩展）的治疗方法：镰状细胞贫血中羟基脲治疗的开放标签II期临床试验。
影响因子：
1.7
作者：
Rankine-Mullings AE;Little CR;Reid ME;Soares DP;Taylor-Bryan C;Knight-Madden JM;Stuber SE;Badaloo AV;Aldred K;Wisdom-Phipps ME;Latham T;Ware RE
通讯作者：
Ware RE